YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
This article first appeared on GuruFocus. Free Cash Flow: Positive free cash flow of $188 million. Operating EBITDAF: Doubled compared to previous periods. Revenue Growth: Operating revenue increased by 10%. Cost Savings: $57 million in gr…
While it may not be enough for some shareholders, we think it is good to see the Ryman Healthcare Limited (NZSE:RYM) share price up 19% in a single quarter. But spare a thought for the long term holders, who have held the stock as it bled…
When researching a stock for investment, what can tell us that the company is in decline? Businesses in decline often have two underlying trends, firstly, a declining return on capital employed (ROCE) and a declining base of capital employ…
This article first appeared on GuruFocus. Revenue Growth: Up 13% driven by pricing and occupancy growth. Free Cash Flow: Positive $56.2 million, first positive result in over a decade. Cost Reduction: Achieved $40 million annualized, with…
Find insight on Abbott, Ryman Healthcare, Novartis and more in the latest Market Talks covering the health care sector. Continue Reading View Comments
Key Insights Significant control over Ryman Healthcare by individual investors implies that the general public has more power to influence management and governance-related decisions The top 25 shareholders own 49% of the company Instituti…
Ryman Healthcare Limited (NZSE:RYM) shareholders should be happy to see the share price up 14% in the last month. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Indeed, the share price is down a whopping 81…
There's been a notable change in appetite for Ryman Healthcare Limited (NZSE:RYM) shares in the week since its full-year report, with the stock down 16% to NZ$2.10. The results were positive, with revenue coming in at NZ$761m, beating anal…
Units and Beds Completed: 950 units and beds completed, the highest ever for Ryman. Cost Savings: $23 million in costs removed in the second half of FY25, with a target to double by the end of the financial year. Free Cash Flow: Improved f…
Key Insights Significant control over Ryman Healthcare by individual investors implies that the general public has more power to influence management and governance-related decisions The top 25 shareholders own 45% of the company Insiders…
Amid easing trade tensions and better-than-expected earnings reports, global markets have shown resilience, with major indices like the S&P 500 and Nasdaq Composite experiencing notable gains. As investors navigate this optimistic yet unce…
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Ryman Healthcare Limited's (NZSE:RYM) case, it's fantastic news for shareholders. While we would never suggest that…
In March 2025, Asian markets are navigating a complex landscape marked by geopolitical tensions and varying economic growth forecasts. Amidst these challenges, investors are increasingly focused on identifying stocks that may be undervalue…
As global markets grapple with inflation concerns and trade uncertainties, Asian small-cap stocks present a compelling area of interest, particularly as these companies often demonstrate resilience and growth potential in dynamic economic…
Key Insights The projected fair value for Ryman Healthcare is NZ$5.74 based on 2 Stage Free Cash Flow to Equity Ryman Healthcare is estimated to be 47% undervalued based on current share price of NZ$3.05 The NZ$5.21 analyst price target fo…
As global markets navigate a landscape marked by interest rate adjustments and competitive pressures in the technology sector, investors are keenly observing the implications for stock valuations. Amidst this volatility, identifying stocks…
Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high. Zooming in on an example, the Ryman Healthcare Limited (NZSE:RYM) share price dropped 73% in the last half decade. We certain…
As global markets navigate a period of cautious optimism marked by recent rate cuts and economic uncertainties, investors are keenly observing the implications of these developments on stock valuations. Amidst this backdrop, identifying st…
Key Insights Significantly high institutional ownership implies Ryman Healthcare's stock price is sensitive to their trading actions 50% of the business is held by the top 16 shareholders Insiders have been selling lately If you want to kn…
In recent weeks, global markets have displayed a notable shift towards small-cap and value shares, with the Russell 2000 Index reflecting a positive trajectory. This trend underscores an environment where discerning investors might find si…
As global markets display mixed reactions with a notable pivot towards small-cap and value shares, investors are keenly observing these segments for potential opportunities. In such an environment, identifying undervalued small-cap stocks…
As of July 2024, global markets are exhibiting a notable shift with investors increasingly turning their focus towards value and small-cap stocks, as evidenced by the Russell indexes which highlight a significant divergence in performance…
Key Insights Ryman Healthcare's estimated fair value is NZ$7.47 based on 2 Stage Free Cash Flow to Equity Ryman Healthcare's NZ$4.15 share price signals that it might be 44% undervalued The NZ$5.96 analyst price target for RYM is 20% less…
If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Ryman Healthcare Limited (NZSE:RYM) have had an unfortunate run in the last three years. Regrettably, they have had to cope with a 71% drop…
Ryman Healthcare (NZSE:RYM) Full Year 2024 Results Key Financial Results Revenue: NZ$689.9m (up 21% from FY 2023). Net income: NZ$4.78m (down 98% from FY 2023). Profit margin: 0.7% (down from 45% in FY 2023). EPS: NZ$0.007 (down from NZ$0.…
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. One common approach is to try and find a company with returns on capital employed (ROCE) that are in…
Over the last year, a good number of insiders have significantly increased their holdings in Ryman Healthcare Limited (NZSE:RYM). This is encouraging because it indicates that insiders are more optimistic about the company's prospects. Whi…
Key Insights Ryman Healthcare's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 42% of the business is held by the top 25 shareholders Institutions own 38% of…
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been particularly tough on longer term Ryman Healthcare Limited (NZSE:RYM) shareholders. Regrettably, they have had to cope…
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the co…
While Ryman Healthcare Limited (NZSE:RYM) might not be the most widely known stock at the moment, it saw its share price hover around a small range of NZ$6.42 to NZ$6.99 over the last few weeks. But is this actually reflective of the share…
In the last year, multiple insiders have substantially increased their holdings of Ryman Healthcare Limited (NZSE:RYM) stock, indicating that insiders' optimism about the company's prospects has increased. Although we don't think sharehold…
Key Insights Ryman Healthcare's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 40% of the business is held by the top 25 shareholders Insiders have been buyi…
While it may not be enough for some shareholders, we think it is good to see the Ryman Healthcare Limited (NZSE:RYM) share price up 29% in a single quarter. But that cannot eclipse the less-than-impressive returns over the last three years…
Key Insights The projected fair value for Ryman Healthcare is NZ$8.21 based on 2 Stage Free Cash Flow to Equity Ryman Healthcare's NZ$6.28 share price signals that it might be 24% undervalued Analyst price target for RYM is NZ$7.80 which i…
Ryman Healthcare Limited (NZSE:RYM), might not be a large cap stock, but it saw significant share price movement during recent months on the NZSE, rising to highs of NZ$6.90 and falling to the lows of NZ$5.24. Some share price movements ca…